CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/28/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. NVDA
9. FDXF
10. RKLB

Go back to CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CorMedix (CRMD) PT Lowered to $9 at RBC Capital

March 13, 2024 6:21 AM EDT

RBC Capital analyst Gregory Renza lowered the price target on CorMedix (NASDAQ: CRMD) to $9.00 (from $10.00) while maintaining a Outperform rating.

The analyst comments "CRMD reported 4Q, with consistent messaging and incremental updates on launch & reimbursement strategy, into the reaffirmed proposed 4/15 inpatient launch, and... More